1103 related articles for article (PubMed ID: 33369247)
1. Modulatory effects of gut microbiome in cancer immunotherapy: A novel paradigm for blockade of immune checkpoint inhibitors.
Rezasoltani S; Yadegar A; Asadzadeh Aghdaei H; Reza Zali M
Cancer Med; 2021 Feb; 10(3):1141-1154. PubMed ID: 33369247
[TBL] [Abstract][Full Text] [Related]
2. Modulation of Gut Microbiota to Enhance Effect of Checkpoint Inhibitor Immunotherapy.
Wu J; Wang S; Zheng B; Qiu X; Wang H; Chen L
Front Immunol; 2021; 12():669150. PubMed ID: 34267748
[TBL] [Abstract][Full Text] [Related]
3. Modulation of gut microbiota to overcome resistance to immune checkpoint blockade in cancer immunotherapy.
Huang J; Jiang Z; Wang Y; Fan X; Cai J; Yao X; Liu L; Huang J; He J; Xie C; Wu Q; Cao Y; Leung EL
Curr Opin Pharmacol; 2020 Oct; 54():1-10. PubMed ID: 32619934
[TBL] [Abstract][Full Text] [Related]
4. Modulation of Gut Microbiota: A Novel Paradigm of Enhancing the Efficacy of Programmed Death-1 and Programmed Death Ligand-1 Blockade Therapy.
Wang Y; Ma R; Liu F; Lee SA; Zhang L
Front Immunol; 2018; 9():374. PubMed ID: 29556232
[TBL] [Abstract][Full Text] [Related]
5. A review on the role of gut microbiota in immune checkpoint blockade therapy for cancer.
Kim E; Ahn H; Park H
Mamm Genome; 2021 Aug; 32(4):223-231. PubMed ID: 33783613
[TBL] [Abstract][Full Text] [Related]
6. The impact of microbiota on PD-1/PD-L1 inhibitor therapy outcomes: A focus on solid tumors.
Najafi S; Majidpoor J; Mortezaee K
Life Sci; 2022 Dec; 310():121138. PubMed ID: 36309224
[TBL] [Abstract][Full Text] [Related]
7. Gut microbiome and cancer immunotherapy.
Sun JY; Yin TL; Zhou J; Xu J; Lu XJ
J Cell Physiol; 2020 May; 235(5):4082-4088. PubMed ID: 31663125
[TBL] [Abstract][Full Text] [Related]
8. The Role of Gut Microbiota in Overcoming Resistance to Checkpoint Inhibitors in Cancer Patients: Mechanisms and Challenges.
Bouferraa Y; Chedid A; Amhaz G; El Lakkiss A; Mukherji D; Temraz S; Shamseddine A
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360802
[TBL] [Abstract][Full Text] [Related]
9. Gut Microbiota in Cancer Immune Response and Immunotherapy.
Zhou CB; Zhou YL; Fang JY
Trends Cancer; 2021 Jul; 7(7):647-660. PubMed ID: 33674230
[TBL] [Abstract][Full Text] [Related]
10. Gut microbiome and cancer immunotherapy.
Li W; Deng Y; Chu Q; Zhang P
Cancer Lett; 2019 Apr; 447():41-47. PubMed ID: 30684593
[TBL] [Abstract][Full Text] [Related]
11. Gold digging: Searching for gut microbiota that enhances antitumor immunity.
Hou F; Pan Z; Yang R; Zhi F; Bi Y
J Cell Physiol; 2021 Aug; 236(8):5495-5511. PubMed ID: 33452716
[TBL] [Abstract][Full Text] [Related]
12. A new biological triangle in cancer: intestinal microbiota, immune checkpoint inhibitors and antibiotics.
Zhang J; Dai Z; Yan C; Zhang W; Wang D; Tang D
Clin Transl Oncol; 2021 Dec; 23(12):2415-2430. PubMed ID: 34125407
[TBL] [Abstract][Full Text] [Related]
13. The Challenge of ICIs Resistance in Solid Tumours: Could Microbiota and Its Diversity Be Our Secret Weapon?
Roberto M; Carconi C; Cerreti M; Schipilliti FM; Botticelli A; Mazzuca F; Marchetti P
Front Immunol; 2021; 12():704942. PubMed ID: 34489956
[TBL] [Abstract][Full Text] [Related]
14. Gut microbiome in cancer immunotherapy: Current trends, translational challenges and future possibilities.
Pandey P; Khan F
Biochim Biophys Acta Gen Subj; 2023 Sep; 1867(9):130401. PubMed ID: 37307905
[TBL] [Abstract][Full Text] [Related]
15. Fine-Tuning Cancer Immunotherapy: Optimizing the Gut Microbiome.
Pitt JM; Vétizou M; Waldschmitt N; Kroemer G; Chamaillard M; Boneca IG; Zitvogel L
Cancer Res; 2016 Aug; 76(16):4602-7. PubMed ID: 27474734
[TBL] [Abstract][Full Text] [Related]
16. PD-1/PD-L1 blockade: Prospectives for immunotherapy in cancer and autoimmunity.
Hosseinzadeh R; Feizisani F; Shomali N; Abdelbasset WK; Hemmatzadeh M; Gholizadeh Navashenaq J; Jadidi-Niaragh F; Bokov DO; Janebifam M; Mohammadi H
IUBMB Life; 2021 Nov; 73(11):1293-1306. PubMed ID: 34538007
[TBL] [Abstract][Full Text] [Related]
17. Manipulating Gut Microbiota Composition to Enhance the Therapeutic Effect of Cancer Immunotherapy.
Yi M; Jiao D; Qin S; Chu Q; Li A; Wu K
Integr Cancer Ther; 2019; 18():1534735419876351. PubMed ID: 31517538
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of primary and acquired resistance to PD-1/PD-L1 blockade and the emerging role of gut microbiome.
Zou R; Wang Y; Ye F; Zhang X; Wang M; Cui S
Clin Transl Oncol; 2021 Nov; 23(11):2237-2252. PubMed ID: 34002348
[TBL] [Abstract][Full Text] [Related]
19. Cancer and the Microbiome-Influence of the Commensal Microbiota on Cancer, Immune Responses, and Immunotherapy.
Matson V; Chervin CS; Gajewski TF
Gastroenterology; 2021 Jan; 160(2):600-613. PubMed ID: 33253684
[TBL] [Abstract][Full Text] [Related]
20. Uncovering the role of the gut microbiota in immune checkpoint blockade therapy: A mini-review.
Halsey T; Ologun G; Wargo J; Jenq RR
Semin Hematol; 2020 Jan; 57(1):13-18. PubMed ID: 32690139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]